about
Intraocular Lymphoma ModelsThe role of anti-inflammatory agents in age-related macular degeneration (AMD) treatmentIntravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics.Future therapies of wet age-related macular degeneration.Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.Vitreous analysis in the management of uveitisIntraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study.Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma.New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?Subcutaneous diffuse large B-cell lymphoma with intraocular involvement.Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes.Enucleation of painful blind eye for refractory intraocular lymphoma after dose-limiting chemotherapy and radiotherapy.Recent progress in the diagnosis and treatment of primary vitreoretinal lymphoma.Primary intraocular lymphoma: a review.THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA.[Special hematological diagnostics and therapy options for ocular lymphoma taking CNS involvement into account].Highly suspected primary intraocular lymphoma in a patient with rheumatoid arthritis treated with etanercept: a case report.
P2860
Q26750423-67A74FCB-F38E-478B-9AA1-432215FFEE7AQ34605896-5E257477-F2C4-4990-A61C-096311BA360CQ35060364-AEB50B41-599E-4730-8579-887061DFE571Q35162495-D9E9BD87-1706-47CA-94EC-1BAA46D2FCBDQ35599811-CC0A5945-75DB-4E81-8D43-386876072D1AQ36369359-7D0F1B02-8CD6-4DCD-ADDE-6B51020CFBC1Q36441439-CADE6795-57F4-4F46-AFFF-F4553FA66129Q37100303-3EB67F6E-73A0-415B-ABEF-EF0C6FCF2C4BQ38057370-0D45A50C-A83F-40ED-91C0-9D7DB28F6EA2Q38194808-26F57C28-800D-4A47-86F4-BE9F365D4C92Q39591140-1CB7A835-173B-4A1B-ACE6-B7F794D5011AQ41037004-163FF31E-2EC1-47CF-9F9B-9B861726EAA2Q42323015-CF37ADCF-B359-4688-ABC6-02B851919EDAQ42336636-EC2137BA-8B6F-4EBF-9DCE-590DFBE9B751Q46228164-2B828743-E500-4C13-81A8-B558902BBDD6Q46732893-B3D55AA2-8A7D-4A29-9F1D-07FC8058F0BFQ52869270-FE806F32-8C5F-4BB1-8676-E07CB1B982B3Q55513964-AD1FDABA-5F90-40EB-92E3-FA59DB262294
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical review: treatment of vitreoretinal lymphoma.
@en
Clinical review: treatment of vitreoretinal lymphoma.
@nl
type
label
Clinical review: treatment of vitreoretinal lymphoma.
@en
Clinical review: treatment of vitreoretinal lymphoma.
@nl
prefLabel
Clinical review: treatment of vitreoretinal lymphoma.
@en
Clinical review: treatment of vitreoretinal lymphoma.
@nl
P2093
P2860
P1476
Clinical review: treatment of vitreoretinal lymphoma.
@en
P2093
C Stephen Foster
Fred H Hochberg
Jacob Pe'er
P2860
P304
P356
10.3109/09273940903370755
P577
2009-09-01T00:00:00Z